Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Fallopian Tube Neoplasms 10 Ovarian Neoplasms 7 Endometrial Neoplasms 5 Breast Neoplasms 4 Prostatic Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Osteosarcoma 2 Neuroendocrine Tumors 2 Neuroblastoma 2 Neoplasms 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Glioma 2 Ependymoma 2 Xanthogranuloma, Juvenile 1 Wilms Tumor 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Recurrence 1

Interventions

Cyclophosphamide 6 fludarabine 4 Standard of Care 4 Practice Guidelines as Topic 3 Mycophenolic Acid 3 GSK2636771 3 venetoclax 2 trametinib 2 talquetamab 2 osimertinib 2 dabrafenib 2 X-Rays 2 Whole-Body Irradiation 2 Thiotepa 2 Tacrolimus 2 Specimen Handling 2 Mesna 2 Melphalan 2 Magnetic Resonance Spectroscopy 2 Filgrastim 2 Biopsy 2 ulixertinib 1 trastuzumab biosimilar HLX02 1 thymoglobulin 1 sapanisertib 1 ruxolitinib 1 relatlimab 1 plerixafor 1 pertuzumab 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hematologic Neoplasms × olaparib × 30 days × Clear all

NCT03486873 2026-06-05

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡